Royal Bank of Canada
IOBT

Royal Bank of Canada’s IO Biotech IOBT Stock Holding History

Royal Bank of Canada’s Portfolio IOBT Stock Details IOBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-60,000
Closed -$55K – 7022
2024
Q4 		$55K Buy
+60,000
New +$59.7K ﹤0.01% 5642

Other funds holding IOBT

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $308M AUM 120.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return
LCM
Landscape Capital Management Englewood, New Jersey $1.54B AUM 30.95% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Royal Bank of Canada's IOBT Position: Q1 2025 in Review

Royal Bank of Canada sold out of IO Biotech (IOBT) in Q1 2025, closing a stake of 60,000 shares — an estimated $55K sold.

Royal Bank of Canada first reported a position in IOBT in Q4 2024 and held it in 1 quarter. The position peaked at $55K in Q4 2024. 22 funds tracked by Wall St. Rank hold IOBT as of Q1 2025.

  • Royal Bank of Canada reported no remaining IO Biotech position as of Q1 2025 after selling out during the quarter.
  • Royal Bank of Canada sold 60,000 IO Biotech shares in Q1 2025, an estimated $55K.
  • Royal Bank of Canada first reported a position in IO Biotech in Q4 2024 and held it in 1 quarter.
  • Royal Bank of Canada's IO Biotech position peaked at $55K in Q4 2024.
  • 22 funds tracked by Wall St. Rank held IO Biotech as of Q1 2025.

Based on Royal Bank of Canada's 13F filing for Q1 2025, filed 15 May 2025.